

AMENDMENTS TO THE CLAIMS

Claims 1 and 2 (previously cancelled)

Claim 3 (currently amended)

The method of claim 18, in which the ~~estradiol derivative is~~ contains 17 β -estradiol.

Claim 4 (currently amended)

The method of claim 18, in which the ~~estradiol derivative is~~ contains estradiol valerate.

Claim 5 (currently amended)

The method of claim 18, in which the ~~estradiol derivative is~~ contains conjugated equine estrogens.

Claim 6 (currently amended)

The method of claim 18, in which the ~~estradiol derivative is present in an amount of~~ composition contains from 0.3 to 3 mg ~~per unitary~~ of estrogenic compound per daily dose.


Claim 7 (currently amended)

The method of claim 18 in which ~~estradiol is present in the free form in an amount~~ the composition contains from 0.5 to 1.5 mg ~~per unitary~~ of free estradiol per daily dose.

Claim 8 (currently amended)

The method of claim ~~15~~ 18, in which ~~estradiol valerate is present in an amount of~~
the composition contains from 1.5 to 2 mg per unitary of an estradiol ester per daily
dose.

Claim 9 (currently amended)

The method of claim ~~5~~ 18, in which composition contains from conjugated equine
~~estrogen is present in an amount of 0.312 to 0.625 mg per unitary~~ of conjugated equine
estrogens per daily dose.

Claim 10 (previously cancelled)

Claims 11 and 12 (currently cancelled)

Claim 13 (currently amended)

The method composition of claim ~~11~~ 18, in which the composition contains from
~~nomegestrol acetate is present in an amount of 0.625 to 1.25 mg per unitary~~ daily dose of
nomegestrol acetate.

Claims 14 to 17 (previously cancelled)

Claim 18 (currently amended)

A method of preventing estrogen deficiencies in menopausal women ~~comprising~~ consisting in continuously orally administering without interruption to menopausal women in need thereof ~~an amount of a composition containing from~~ 0.3 to 3 mg of an estrogenic compound ~~estradiol derivative~~ selected from the group consisting of free estradiol, estradiol esters, 17 β -estradiol, esterified 17 β -estradiol and conjugated equine estrogens and from 0.3 to 1.25 mg of nomegestrol acetate per daily dose ~~or one of its~~ esters.

Claim 19 (currently amended)

A method of preventing osteoporosis ~~and cardiovascular disorders~~ in menopausal women ~~comprising~~ consisting in continuously orally administering without interruption to menopausal women in need thereof ~~an amount of a composition of~~ 0.3 to 3 mg of an estrogenic compound ~~estradiol derivative~~ selected from the group consisting of free estradiol, estradiol esters 17 β -estradiol, esterified 17 β -estradiol and conjugated equine estrogens and from 0.3 to 1.25 mg of nomegestrol acetate per daily dose ~~or one of its~~ esters ~~sufficient to prevent osteoporosis and cardiovascular disorders.~~

Prevent
Osteo
Cardiovascular


Claim 20 (currently amended)

The method of claim 19 in which the ~~estradiol derivative~~ is compositon contains 17 β -estradiol.

Claim 21 (currently amended)

The method of claim 19 in which the composition contains estradiol derivative is estradiol valerate.

Claim 22 (currently amended)

The method of claim 19, in which the composition contains ~~estradiol derivative~~ equine estrogen is present in an amount ranging from 0.3 to 3 mg ~~per unitary~~ of estrogenic compound per daily dose.

Claim 23 (currently amended)

The method of claim 19, in which the ~~estradiol derivative is~~ composition contains conjugated equine estrogens.

Claim 24 (currently amended)

The method of claim ~~19~~ 18, in which the composition contains from estradiol derivative is present in an amount of 0.3 to 3 mg of estrogenic compound per daily ~~per unitary~~ dose.


Claim 25 (currently amended)

The method of claim 19 in which the composition contains from ~~estradiol is~~ present in the free form in an amount of 0.5 to 1.5 mg of free estradiol per unitary daily dose.

Claim 26 (currently amended)

The method of claim 19 in which composition contains from ~~estradiol valerate~~ is ~~present in an amount of~~ 1.5 to 2 mg of an estradiol per daily unitary dose.

Claim 27 (currently amended)

The method of claim ~~18~~ 19, in which the composition contains from ~~conjugated~~ equine estrogen is ~~present in an amount of~~ 0.312 to 0.625 mg of conjugated equine estrogens per ~~unitary~~ daily dose.

Claims 28 and 29 (currently cancelled)

Claim 30 (currently amended)

The method of claim 19, in which the composition contains from ~~norgestrol~~ acetate is ~~present in an amount of~~ 0.625 to 1.25 mg of norgestrol acetate per ~~unitary~~ dose.

Claim 31 (currently added)

A pharmaceutical composition for hormone replacement therapy, said composition being in oral administrable form and comprising, in combination, 0.3 to 3 mg of an estrogenic compound selected from the group consisting of free estradiol or esterified estradiol and 0.3 to 1.25 mg of nomegestrol acetate.

Claim 32 (currently added)

A pharmaceutical composition for hormone replacement therapy, said composition being in oral administrable form and comprising, in combinatino, 0.3 to 3 mg of conjugated equine estrogens and 0.3 to 1.25 mg of nomegestrol acetate.